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SIGNIFICANCE
Mechanobullous epidermolysis bullosa acquisita, porphyria 
cutanea tarda and pseudoporphyria are mechanobullous di­
seases that have many clinical similarities, but have a different 
pathogenesis and need different treatment. It is therefore 
important to separate these entities. We performed a retro­
spective observational study to compare clinical and labora­
tory data, in particular direct immunofluorescence, of these 
patient groups in order find discriminatory features. Careful 
examination of these data revealed (subtle) differences, alt­
hough many overlapping features are present. There fore, 
integrating all clinical and laboratory data is essential to dif­
ferentiate between mechanobullous epidermolysis bullosa 
acquisita, porphyria cutanea tarda and pseudoporphyria.
Mechanobullous epidermolysis bullosa acquisita 
(mEBA) can have a clinical presentation that is very 
similar to other blistering diseases, such as porphyria 
cutanea tarda (PCT) and pseudoporphyria. Direct im-
munofluorescence is an important feature in the diag-
nosis of mEBA, although features that overlap with PCT 
and pseudoporphyria have been reported. This retro-
spective observational study investigated whether di-
rect immunofluorescence can discriminate mEBA from 
PCT and pseudoporphyria. Biopsies of 13 patients with 
mEBA, 10 with PCT and 10 with pseudoporphyria were 
included. In 7 cases of PCT and 4 of pseudopor phyria, 
direct immunofluorescence showed a pattern at the 
dermal–epidermal junction that appeared similar to 
the u-serrated pattern in mEBA. Vessel wall deposi-
tions were observed in all 3 diseases, but were more 
frequent and more intense in PCT and pseudoporphy-
ria than in mEBA. Careful examination of direct immu-
nofluorescence of mEBA vs. PCT and pseudoporphyria 
revealed different staining patterns, although overlap-
ping features were present. Therefore, integrating all 
clinical and laboratory data is essential to differentiate 
between mEBA, PCT and pseudoporphyria.
Key words: mechanobullous epidermolysis bullosa acquisita; 
porphyria cutanea tarda; pseudoporphyria; direct immunofluo­
rescence microscopy.
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Epidermolysis bullosa acquisita (EBA) is a rare sub-epidermal autoimmune bullous disease. The classic 
mechanobullous subtype (mEBA) may mimic porphyria 
cutanea tarda (PCT) and pseudoporphyria. Clinically 
these diseases are characterized by acral blisters that heal 
with atrophic scarring and milia, whereas histological 
examination shows cell-poor subepidermal blistering 
in all 3 entities. Although higher sensitivities have been 
reported (1, 2), in our experience serology has a sensi-
tivity of only 40% for salt-split skin (SSS) and 45% for 
NC1/NC2 type VII collagen enzyme-linked immunoas-
say (ELISA) in patients with EBA (3), serration pattern 
analysis by direct immunofluorescence microscopy (DIF) 
is considered of the utmost importance for diagnosis. 
In EBA in vivo depositions of immunoglobulins at the 
epidermal basement membrane zone (BMZ) are usually 
in a u-serrated linear pattern (4), whereas in PCT and 
pseudoporphyria homogenous depositions of fibrinogen, 
complement and immunoglobulins are found in the BMZ 
of epidermis and vessel walls (5, 6). However, in daily 
practice mEBA, PCT and pseudoporphyria can show 
very similar epidermal BMZ staining patterns. DIF pat-
terns of mEBA, PCT and pseudoporphyria have never 
been compared systematically. The aim of this study is 
to re-evaluate clinical information and histopathology 
of confirmed mEBA, PCT and pseudoporphyria cases 
and to repeat DIF on archived frozen biopsies in order 




Patients were selected from the biobank of the Center for Blistering 
Diseases of the University Medical Center Groningen (UMCG) 
for the period 1990 to 2016. Inclusion criteria for mEBA were: 
(i) mechanobullous blisters, (ii) a u-serrated pattern of linear im-
munodeposits of IgG at the epidermal BMZ by DIF of skin tissue, 
and/or (iii) dermal staining on SSS substrate and/or autoantibodies 
to type VII collagen established by NC1/NC2 type VII collagen 
ELISA and/or reactivity to the 290-kDa band by immunoblot on 
dermal extract. The mEBA patients have been reported previously 
(7), but do not represent our total mEBA population, since only 
those patients with positive serological results were included in 
this study. Inclusion criteria for PCT were: (i) blisters on sun-
exposed skin, with (ii) elevated porphyrin levels in urine and/or 
serum. Inclusion criteria for pseudoporphyria were: (i) blisters 
on sun-exposed skin, with (ii) no elevation of porphyrin levels 
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in urine and/or serum, and (iii) remission of cutaneous disease 
after cessation of the causative drug and/or sun exposure. At the 
time biopsies were obtained, all patients consented to the use of 
material for further diagnostic or research purposes in the future. 
In this retrospective study, no approval by the ethics committee 
in the Netherlands was required according to national regulations.
Direct immunofluorescence microscopy
The frozen biopsies were cut to 4-µm thick sections and stained 
for DIF with IgG, IgA, IgM, fibrinogen and C3c, as described 
previously (4). The sections were examined with a Leica DMRA 
fluorescence light microscope (Leica, Wetzlar, Germany). DIF 
staining intensities were graded from 1+ to 4+ by 2 blinded 
observers (HdG and GD). Fluorescence photographs were taken 
of the epidermal BMZ and the dermal blood vessels of each of 
the slides using a Leica DFC350FX camera. Leica Application 
Suite software (version 3.8.0) and Adobe Photoshop CS6 (version 
13.0.1 ×32) were used for further image processing. Fluorescence 
overlay antigen mapping (FOAM) was used to map in vivo bound 
IgG at the epidermal BMZ with type VII collagen. This was 
performed in 2 cases of mEBA, 3 cases of PCT and one case of 
pseudoporphyria, which showed an IgG serration pattern at the 
epidermal BMZ very similar to the u-serration pattern of mEBA. 
The mapping procedure included 3 successive immunostaining 
steps, with incubation at room temperature for 30 min and rinsing 
with PBS for 15 min between each step. The first step involved 
adding mouse anti-human type VII collagen IgG (LH7.2) to the 
frozen sections. Secondly, highly cross-absorbed Alexa Fluor® 
568 goat anti-mouse IgG (Molecular Probes Europe, Leiden, 
The Netherlands) was added. The third step involved adding Fc-
specific FITC-conjugated goat F(ab’)2 anti-human IgG (Protos 
Immunoresearch, USA). Lastly, bisbenzimide (Hoechst 33258) 
was placed on the slides and incubated for 5–10 min to provide 
nuclear staining. Afterwards the slides were washed with PBS 
for 15 min and a coverslip with a drop of SlowFade® was placed 
on each section.
Clinical information, histopathological and laboratory findings
All clinical information and photodocumentation for patients 
was collected from the UMCG electronic patient file system. 
When available, histopathological slides of haematoxylin-eosin- 
(H&E) and periodic acid-Schiff- (PAS) stained paraffin sections 
were examined by light microscopy. Other previously performed 
laboratory test results were retrieved from our database: indirect 
immunofluorescence with SSS, immunoblot analysis on reactivity 
to the 290-kDa antigen on human dermal extract, and type VII col-
lagen ELISA. In mEBA, results from SSS showed dermal staining 
in 10 cases (77%). Immunoblot reactivity to the 290-kDa band 
was present in 6 cases (46%), and ELISA to type VII collagen was 
positive in 8 cases (67%). 
RESULTS
Clinical features
The patients’ clinical characteristics are shown in Table 
I. A total of 13 patients with mEBA were included. In all 
but 1 patient, the diagnosis of mEBA was confirmed by 
serology. In patient 1 there was a very clear u-serrated 
Table I. Clinical characteristics of 13 patients with mechanobullous epidermolysis bullosa acquisita (mEBA), 10 with porphyria cutanea 
tarda (PCT) and 10 with pseudoporphyria (PSP) 
Pat. No./Sex/




disorder Scars Milia Diagnosis
1/F/47 Erosions, papules, crusts, pruritus Extremities, face, neck, back + – + + mEBA
2/F/46 Blisters, erythema, excoriations, pruritus Extremities, groins + D + ++ mEBA
3/F/35 Blisters, erosions, pruritus Hands, arms, trunk – D + ++ mEBA
4/F/39 Blisters, erosions, pruritus Extremities, groins, abdomen + D + ++ mEBA
5/M/31 Blisters, plaques, crusts Extremities, trunk, back + D – ++ mEBA
6/F/19 Blisters, erosions, crusts, erythema, pruritus Extremities, back + D + ++ mEBA
7/F/75 Blisters, erosions, erythema, crusts, pruritus Extremities, scalp, face, neck + – – – mEBA
8/F/59 Blisters, erosions Extremities – D * + mEBA
9/M/43 Blisters, erosions Arms, feet, knees + D + ++ mEBA
10/M/29 Blisters, crusts Extremities + – – ++ mEBA
11/M/67 Blisters * * * * * mEBA
12/F/31 Blisters, erythema Extremities + D + ++ mEBA
13/M/41 * * + * * * mEBA
14/F/58 Erosions, crusts Hands – – + + PCT
15/F/39 Blisters, erosions, crusts, pruritus,
hypertrichosis.
Hands, feet, face, ears, neck – – – – PCT
16/M/63 Erosions, crusts, erythema, pruritus Hands – – – + PCT
17/M/71 Blisters, erosions Hands – – * * PCT
18/F/70 Blisters, erythema, pruritus Feet – – – – PCT
19/M/59 Blisters Hands * * * * PCT
20/F/62 Blisters Hands, feet – – – – PCT
21/M/53 Blisters, erosions Hands – – – – PCT
22/M/73 Blisters, crusts, pruritus Hands, scalp, face – * + – PCT
23/M/58 Blisters, crusts, erythema, pruritus Hands – – – + PCT
24/M/57 Blisters, crusts, pruritus Hands, feet – – + – PSP
25/F/66 Blisters, crusts, erythema, pruritus Feet – – – – PSP
26/M/42 Blisters Hands – – – – PSP
27/M/66 Blisters, erosions, crusts Hands, lips – – + – PSP
28/F/64 Blisters, excoriations, pruritus Hands, arms, neck, back – – + + PSP
29/F/52 Blisters Hands – – – – PSP
30/M/61 Blisters, erosions Hands, feet – – – – PSP
31/F/52 Blisters, erosions Hands – – – – PSP
32/F/50 Blisters, erythematous maculae Hands, feet – – – – PSP
33/F/44 Blisters, pruritus Hands, feet – O + + PSP
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pattern by DIF, but negative serology; however, antigen 
mapping with type VII collagen confirmed mEBA as 
the diagnosis. The median age at diagnosis was 41 years 
(range 19–75 years) of mEBA patients was younger than 
PCT (60.5; range 39–73 years) and pseudoporphyria 
patients (54.5; range 42–66 years). In all mEBA patients 
the skin manifestations were not limited to the hands and 
feet. In 7 mEBA patients erosions healed with scars, and 
milia were present in 10 cases (Fig. 1A and C). For both 
PCT and pseudoporphyria, the skin manifestations were 
limited to the hands and/or feet in 16 out of 20 patients, 
with scarring and milia occurring less frequently and 
less severely than in mEBA (Fig. 1B and D). In mEBA, 
mucosal involvement was present in 10 cases (Fig. 1F). 
In all of these cases the oral mucosa was involved, in one 
case there was also genital, nasal and ocular involvement. 
In PCT and pseudoporphyria, none of the patients had 
mucosal involvement. Nail dystrophy was present in 8 
mEBA cases, in 4 of those cases 1 or more nails were 
completely absent (Fig. 1E). In PCT and pseudoporphyria 
nail dystrophy was not present. In patient 33 there was a 
nail abnormality characterized by mild distal onycholysis 
of the toenails of the halluces, but it is uncertain whether 
this was related to the pseudoporphyria. 
Direct immunofluorescence microscopy
All immunological findings are shown in Table II. In 
mEBA, DIF examination showed a linear/u-serrated 
pattern of IgG depositions at the epidermal BMZ in 12 
cases (Fig. 2a), in one case the pattern was undetermined. 
Coarse clumps of IgG depositions at the epidermal BMZ 
were observed in 3 cases (23%, Fig. 2b). In PCT and pseu-
doporphyria, the depositions at the epidermal BMZ were 
mostly homogenous, but there was a variation of patterns. 
In 7 PCT and 4 pseudoporphyria cases, parts of the depo-
sitions at the epidermal BMZ appeared very similar to a 
u- or n-serrated pattern (Fig. 2c–e). Mostly, they were not 
as intense and not as finely delineated, although in some 
instances it was difficult to discern between mEBA and 
Fig. 1. Clinical manifestations of epidermolysis bullosa acquisita (EBA), porphyria cutanea tarda (PCT) and pseudoporphyria. (A) Blister on 
the arm of patient 6 (EBA). (B) Tense bulla on finger and excoriations and reddish-brown maculae with a few milia on the dorsal side of the hand of patient 
28 (pseudoporphyria). (C) Pink erythematous papules with milia on the dorsal side of the hand of patient 5 (MB-EBA). (D) Erythematous plaques with 
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(pseudo)porphyria. In these cases the depositions were 
called “pseudo-serrated”. Vessel wall depositions were 
present in 4 mEBA cases, although less intense than the 
depositions at the epidermal BMZ. In PCT and pseudo-
porphyria, vessel wall staining was present in all patients 
but 1 (Fig. 2c). Patient 21 only showed depositions at the 
epidermal BMZ. Mostly the depositions in the vessel 
walls were of similar intensity or more intense than the 
depositions at the epidermal BMZ (Fig. 2f). Compared 
with mEBA, vessel wall depositions in PCT and pseudo-
porphyria showed more intense staining.
FOAM mapping in vivo bound IgG with type VII 
collagen showed in PCT and pseudoporphyria that 
the pseudo-u-serrated parts of IgG depositions at the 
epidermal BMZ had an almost complete overlap with 
type VII collagen, although some depositions appeared 
to be below and above type VII collagen (Fig. 2g–i). As 
expected, in mEBA there was a complete overlap of IgG 
with type VII collagen (not shown).
Histopathological findings
Histopathological sections were available for 2 patients 
with mEBA, 3 with PCT and 8 with pseudoporphyria. 
All showed cell-poor subepidermal blisters (Fig. 3). 
Festooning was present in all cases of PCT and 3 cases 
of pseudoporphyria (38%), as well as in one case of 
EBA (50%). The PAS- and collagen IV-stains showed 
thickening of vessel walls in all cases of PCT and 5 cases 
of pseudoporphyria (63%), but in none of the cases of 
mEBA. Caterpillar bodies were observed in one case of 
PCT (33%) and one of pseudoporphyria (13%).
Table III summarizes the differences and similarities 
of mEBA, PCT and pseudoporphyria that can be derived 
from this study.
DISCUSSION
This study comparing mEBA, PCT and pseudopor-
phyria shows that, at first sight, these bullous diseases 
Table II. Immunopathological characteristics
Pat. No./Diagnosis
Direct immunofluorescence IIF Immunoassays
EBMZ Serration pattern Vessel walls SSS dermal ELISA IB
1/mEBA C2+G3+ lin u­serrated A2+FG3+ hom – – –
2/mEBA G3+ lin/cc u­serrated – G3+ – –
3/mEBA G3+ lin u­serrated FAM+G2+ hom C+ gr – + –
4/mEBA M+AC3+G4+ lin u­serrated – G3+A+ + +
5/mEBA A+G3+lin C2+gr u­serrated – G3+ + +
6/mEBA A+ G3+C+/3+ lin u­serrated – G+ + –
7/mEBA G2+C3+ lin/cc Undetermined – G+ + +
8/mEBA G4+u A2+M3+gr
C2+lin
u­serrated AG2+ hom/gr G2+/3+ + +
9/mEBA G2+lin C+gr u­serrated – + – +
10/mEBA G+ u­serrated – G+ + –
11/mEBA G2+ u­serrated C2+ gr G2+/3+ – –
12/mEBA G3+ lin C3+gr u­serrated – – + –
13/mEBA MC2+G3+ lin/cc u­serrated – G+A+ NP +
14/PCT A+FM2+G3+ hom Undetermined A2+F3+G4+ hom
MC2+ hom/gr
NP NP NP
15/PCT A+F2+G3+ hom Undetermined M+FAC2+ G3+ hom – NP NP




FAMC2+G3+ hom – – NP
17/PCT FA+G2+ hom Pseudo­u­serrated FA3+G4+ hom C+ gr NP NP NP
18/PCT F+G2+ hom Pseudo­u­serrated FA2+G3+ hom C+ gr – NP –
19/PCT FM+A2+G3+ hom Pseudo­u­serrated M+FA2+G3+ hom
C+ gr
– NP NP
20/PCT FMAC2+G3+ hom Pseudo­u­serrated MAC2+F3+G4+ hom NP NP NP




– – NP NP
22/PCT A2+G3+ hom Undetermined A2+G3+ hom – NP NP
23/PCT AG2+ hom Pseudo­u­serrated A2+G3+ hom – NP NP
24/PSP FA+G3+ hom Pseudo­u­serrated FA2+G3+ hom C+ gr – NP –
25/PSP – Undetermined FA+G2+hom MC2+ gr – – NP
26/PSP Focally C2+ gr Undetermined A2+G3+hom MC2+ gr – NP NP





28/PSP M+AFG2+ hom 
C+ gr
Pseudo­u­serrated FMC2+AG3+ hom – NP NP
29/PSP FAC2+G3+ hom Pseudo­u­serrated M+FAC2+G3+ hom – NP NP
30/PSP F+MAG2+ hom Undetermined FAM2+G3+ hom NP NP NP
31/PSP F+G2+ hom M+ gr Undetermined AM+ F2+G3+ hom – NP –
32/PSP G+ hom Undetermined A2+G3+ hom 
MC+F2+ gr
– NP NP
33/PSP FAC2+G3+ hom Pseudo­u­serrated M+FAC2+ G3+ hom – NP NP
Direct immunofluorescence staining intensities were graded from 1+ to 4+. A: immunoglobulin A; C: complement component 3; cc: coarse clumps; EBMZ: epidermal 
basement membrane zone; ELISA: enzyme-linked immunosorbent assay to type VII collagen; F: fibrinogen; G: immunoglobulin G; gr: granular; hom: homogenous; 
IB: immunoblot reactivity to the 290-kDa band on dermal extract; IIF: indirect immunofluorescence; lin: linear; M: immunoglobulin M; NP: not performed; SSS: salt 
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Fig. 2. Direct immunofluorescence microscopy. (a) u-serrated depositions of immunoglobulin IgG (3+) at the epidermal basement membrane zone 
(BMZ) in patient 1 (epidermolysis bullosa acquisita; EBA). Insert shows the u­serrated pattern in detail (b), “coarse clumps” depositions of IgG (3+) at 
the epidermal BMZ in patient 13 (EBA). (c) Partly pseudo-u-, partly pseudo-n-serrated (arrow) depositions of IgG (+) at the epidermal BMZ in patient 
21 (porphyria cutanea tarda; PCT). Insert shows the pseudo-u-serrated pattern in detail. (d) Pseudo-u-serrated depositions at the epidermal BMZ (3+) 
and homogenous depositions of IgG in vessel walls (3+) in patient 29 (pseudoporphyria). (e) Homogenous depositions (3+) at the epidermal BMZ with 
homogenous depositions of IgG in vessel walls (4+) (arrow) in patient 20 (PCT). (f) Classic intense depositions of IgG (4+) in vessel walls and homogenous 
depositions (3+) at the epidermal BMZ in patient 14 (PCT). Fluorescent overlay antigen mapping of a porphyria patient. (g) IgG depositions showing a 
pseudo-u-serrated pattern at the epidermal BMZ in green. (h) Staining of collagen type VII in red. (i) Overlay of IgG and collagen type VII, showing IgG 
and collagen type VII, partially overlapping in orange. Bars: (a–e, g–i) 20 μm, (f) 150 μm.
Fig. 3. Histological findings in porphyria cutanea tarda (PCT). Periodic acid­Schiff (PAS)­stain shows: (A) festooning of the dermal papillae (arrows) 
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can have similar immunofluorescence staining patterns, 
although, on close examination, differences can be 
revealed. 
DIF showed a u-serrated pattern of IgG and com-
plement depositions at the epidermal BMZ in 92% of 
the cases of mEBA in the current study. In PCT and 
pseudoporphyria, mainly homogenous depositions of 
IgG were seen at the epidermal BMZ. However, in a 
substantial number of PCT and pseudoporphyria cases 
a pseudo-serrated pattern was observed in a section of 
the slide. Comparing these pseudo-serrated depositions 
to the u-serrated depositions seen in mEBA, it varied 
from a very weak to a strong resemblance. However, 
it can be said that in (pseudo)porphyria the depositions 
at the epidermal BMZ were less intense and less finely 
delineated compared with mEBA. Little research has 
been performed so far in this area, but a u-serrated pattern 
in PCT has been observed previously (8), underscoring 
the potential difficulty of separating EBA from (pseudo)
porphyria with DIF. 
FOAM analysis showed that, similar to mEBA, in 
PCT and pseudoporphyria the IgG depositions overlap-
ped with type VII collagen, explaining that a serration 
pattern similar to the u-serration in mEBA can be found. 
This suggests that photo-active substances, such as 
por phyrins or active drug metabolites and formed im-
mune complexes, are deposited at the same height as 
collagen VII. In 2 cases of PCT in our group, not only 
a pseudo-u-serrated pattern was seen, but also focally 
a pseudo-n-serrated pattern. Vodegel et al. (4) studied 
157 biopsies from patients with subepidermal autoim-
mune bullous diseases and found that the 2 serration 
patterns did not coexist. Therefore, if both patterns are 
seen in one biopsy this should raise the suspicion of 
(pseudo)porphyria.
Deposition of immunoglobulins in the BMZ of ves-
sel walls is a feature frequently described in PCT and 
pseudoporphyria. mEBA, PCT and pseudoporphyria all 
showed some degree of vessel wall staining in the papil-
lary dermis, although in PCT and pseudoporphyria vessel 
wall depositions were found in almost all cases, whereas 
in mEBA this was present in approximately one-third 
of cases. Moreover, the staining of immunoglobulins in 
the vessel walls was more intense in PCT and pseudo-
porphyria than in mEBA. In this respect, Gupta et al. (9) 
stated that PCT can mimic mEBA clinically, but that DIF 
depositions around the vessel walls distinguishes mEBA 
from PCT. A new finding in our study is that vessel wall 
depositions can occur in all 3 diseases, but the intensity 
of the staining is important to differentiate mEBA from 
(pseudo)porphyria. 
However, one of the cases of PCT in our study showed 
deposition of immunoglobulins at the epidermal BMZ 
without vessel wall depositions. This was also observed 
in a previous study of DIF in a total of 28 patients with 
PCT that took biopsies in 3 phases: before treatment, 
during clinical remission and during biochemical remis-
sion (5). Supporting our results, of the 23 biopsies that 
were taken before treatment, DIF showed homogenous 
and intense depositions at the epidermal BMZ and in 
vessel walls. However, in 2 cases of PCT before treat-
ment, they observed depositions of IgG at the epidermal 
BMZ without depositions in the vessel walls. In one of 
those patients a second biopsy was taken during clinical 
remission, in which DIF showed depositions of immu-
noglobulins in the vessel walls while the depositions at 
the epidermal BMZ were no longer present. This sug-
gests that the biopsy of our patient was probably taken 
at a time-point in the active phase when there was not 
yet any vessel wall deposition.
Besides immunofluorescence this study also shows 
that, on dermatological examination, differences bet-
ween mEBA and (pseudo)porphyria could be observed. 
Mucous membrane involvement and nail dystrophy were 
present only in mEBA. Mucosal involvement is said to 
be present frequently in mEBA. In this respect, Iranzo et 
al. (10) found mucous membrane involvement in 3 out 
of 5 mEBA patients. In contrast, mucosal involvement 
in PCT and pseudoporphyria is not a dominant feature, 
although it has rarely been described (11). Similar to 
our study, nail dystrophy is reported to be common in 
mEBA (9, 12). Nail dystrophy is not known to occur in 
(pseudo)porphyria, although another nail abnormality, 
photo-onycholysis, has been described (13, 14). This, 
however, was not present in any of the 20 patients with 
(pseudo)porphyria in the current study. A third distinctive 
clinical feature was the more extensive presence of milia 
and scarring in the patients with mEBA.
Table III. Comparison of mechanobullous epidermolysis bullosa 






  Offending agent None None Present
  Photosensitivity None Present Present
Physical examination
  Distribution Whole body Hands/feet Hands/feet
  Mucosal involvement Present Not present Not present
  Nail dystrophy Present Not present Not present
  Milia/scarring Abundant Limited Limited
Laboratory examination
  Urinary porphyrins Normal Elevated Normal
Histology
  Cell poor blister Present Present Present
  Festooning Present Present Present
  Thickened vessel walls Not present Present Present
  Caterpillar bodies Not present Present Present
Direct IF
  Linear dermal-epidermal 
  Ig/complement deposition








  Ig vessel wall deposition + +++ +++
Indirect IF
  Salt­split skin Dermal deposition Negative Negative
  Immunoblot col VII Positive Negative Negative
  ELISA col VII Positive Negative Negative
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Since histopathological biopsies were not present 
for all patients, results have to be interpreted with care. 
However, we could discern several histological features 
that are specific for (pseudo)porphyria. In the first place, 
thickened walls of papillary blood vessels were found in 
all PCT cases and in almost all pseudoporphyria cases, 
whereas this was not present in either of the 2 cases of 
mEBA. Thickened blood vessel walls have been descri-
bed as a common feature in PCT and pseudoporphyria 
(5, 12, 15, 16). 
A second distinctive feature were so-called caterpil-
lar bodies (Fig. 2), which were present in one case of 
PCT and 1 of pseudoporphyria, but in none of the cases 
of mEBA. It is known that these eosinophilic, linear-
arranged segmented bodies found in the blister roof are 
seen mostly in the porphyrias (17). Similar to our study, 
Egbert et al. (18) found caterpillar bodies, not only in 
PCT, but in pseudoporphyria too. 
Festooning is recognized as a classic feature of PCT 
and pseudoporphyria (13, 16, 17). Indeed, festooning 
was found in all our cases of PCT and 38% of cases of 
pseudoporphyria. Although it has been reported that 
mEBA lacks festooning (19), festooning was observed 
in one of our patients with mEBA. This supports earlier 
findings, showing festooning in mEBA in 2 out of 4 
reviewed cases of mEBA (17).
Limitations
A limitation of the current study is that, due to its retro-
spective nature, not all serological tests were performed 
in the PCT and pseudoporphyria groups. Although, 
serology on SSS was performed in a majority of cases 
(and was negative in all cases), we cannot completely 
rule out concomitant mEBA. Conversely, in the mEBA 
patients porphyrins were not measured, thus PCT is also 
not completely ruled out in these patients.
Conclusion
The results of the current study support the general con-
ception that mEBA, PCT and pseudoporphyria can have 
very similar clinical, histopathological and DIF features. 
Given the fact that these diseases are so alike, the first 
step in the diagnostic work-up is to order urine analysis 
for porphyrins. DIF has substantial value in the diagnostic 
work-up in order to differentiate EBA from PCT and 
pseudoporphyria, but on its own it cannot be regarded 
as the gold standard. In a patient with a mechanobullous 
skin disease, it is essential to integrate all clinical and 
laboratory data in order to differentiate between mEBA, 
PCT and pseudoporphyria. 
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